Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Oliver Tracie | Chief Commercial Officer | Jul 02 '24 | Sale | 25.28 | 9,394 | 237,480 | 127,107 | Jul 03 05:27 PM | | Vakiener Victoria | Director | May 02 '24 | Sale | 23.31 | 1,799 | 41,935 | 30,205 | May 06 06:04 PM | | Hamilton James C | Chief Discovery/Trans Medicine | Apr 01 '24 | Sale | 28.03 | 6,000 | 168,180 | 204,851 | Apr 03 06:05 PM | | Lu Hongbo | Director | Mar 19 '24 | Buy | 28.00 | 1,000 | 28,000 | 32,680 | Mar 20 07:06 PM | | Lu Hongbo | Director | Mar 20 '24 | Buy | 27.50 | 1,000 | 27,500 | 33,680 | Mar 20 07:06 PM | | Lu Hongbo | Director | Mar 18 '24 | Buy | 27.49 | 1,000 | 27,490 | 31,680 | Mar 20 07:06 PM | | Myszkowski Kenneth Allen | Chief Financial Officer | Mar 06 '24 | Sale | 35.19 | 40,000 | 1,407,600 | 400,600 | Mar 08 05:54 PM | | Anzalone Christopher Richard | Chief Executive Officer | Jan 31 '24 | Option Exercise | 14.54 | 57,499 | 836,035 | 3,772,547 | Feb 02 05:25 PM | | Anzalone Christopher Richard | Chief Executive Officer | Jan 31 '24 | Sale | 32.35 | 57,499 | 1,860,019 | 3,715,048 | Feb 02 05:25 PM | | Hamilton James C | Chief Discovery/Trans Medicine | Jan 12 '24 | Sale | 36.89 | 7,940 | 292,904 | 210,851 | Jan 17 06:32 PM | | GIVEN DOUGLAS B | Director | Jan 11 '24 | Sale | 38.06 | 2,911 | 110,788 | 129,711 | Jan 16 06:06 PM | | Waddill William D. | Director | Jan 11 '24 | Sale | 38.07 | 3,934 | 149,759 | 47,870 | Jan 16 06:06 PM | | Ferrari Mauro | Director | Jan 11 '24 | Sale | 38.06 | 3,147 | 119,787 | 60,778 | Jan 16 06:06 PM | | Vakiener Victoria | Director | Jan 11 '24 | Sale | 38.10 | 4,720 | 179,813 | 32,001 | Jan 16 06:06 PM | | Oliver Tracie | Chief Commercial Officer | Jan 05 '24 | Sale | 33.89 | 74 | 2,508 | 136,501 | Jan 08 05:17 PM | | Myszkowski Kenneth Allen | Chief Financial Officer | Jan 05 '24 | Sale | 35.27 | 16,104 | 567,910 | 440,600 | Jan 08 05:16 PM | | San Martin Javier | Chief Medical Officer | Jan 05 '24 | Sale | 35.26 | 8,303 | 292,804 | 198,497 | Jan 08 05:16 PM | | Hamilton James C | Chief Discovery/Trans Medicine | Jan 05 '24 | Sale | 35.18 | 32,143 | 1,130,748 | 218,791 | Jan 05 08:02 PM | | Hamilton James C | Chief Discovery/Trans Medicine | Jan 03 '24 | Sale | 32.19 | 6,300 | 202,781 | 175,934 | Jan 05 08:02 PM | | O'Brien Patrick | COO and General Counsel | Jan 05 '24 | Sale | 35.27 | 22,841 | 805,716 | 464,385 | Jan 05 07:58 PM | | O'Brien Patrick | COO and General Counsel | Jan 03 '24 | Sale | 32.28 | 8,749 | 282,439 | 403,826 | Jan 05 07:58 PM | | O'Brien Patrick | COO and General Counsel | Jan 04 '24 | Sale | 32.63 | 1,600 | 52,208 | 402,226 | Jan 05 07:58 PM | | Anzalone Christopher Richard | Chief Executive Officer | Jan 02 '24 | Sale | 31.01 | 9,952 | 308,637 | 3,715,048 | Jan 04 05:25 PM | | Anzalone Christopher Richard | Chief Executive Officer | Dec 20 '23 | Sale | 28.54 | 12,000 | 342,480 | 3,725,000 | Dec 22 05:04 PM |
|
